SCPH - Scpharmaceuticals Inc
Scpharmaceuticals Inc Logo

SCPH - Scpharmaceuticals Inc

https://www.scpharmaceuticals.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal - scPharmaceuticals ( NASDAQ:SCPH ) , MannKind ( NASDAQ:MNKD )
Benzinga • 2 weeks, 6 days ago • score: 0.22
MannKind to buy scPharmaceuticals for $5.35 per share plus CVR, valuing the deal at up to $360 million. Furoscix sales rose 96% YoY in H1 2025, with Q3 sNDA submission planned for ReadyFlow Autoinjector. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →
Bullish
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
GlobeNewswire • 3 weeks ago • score: 0.39
• Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need • Upfront cash payment of $5.35 per share plus one non-tradable contingent ...
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

scPharmaceuticals Inc., a pharmaceutical company, is engaged in the development and commercialization of various pharmaceutical products. The company is headquartered in Burlington, Massachusetts.

52W High
$6.28
52W Low
$1.94
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.35
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-6.69
EV/Revenue (<3 favorable)
6.22
P/S (TTM) (<3 favorable)
5.98
P/B (<3 favorable)
28.45
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
5.98%
Institutions (25–75% balanced)
75.72%
Shares Outstanding
53,679,000
Float
32,683,600
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
49,969,000
Gross Profit (TTM)
34,211,000
EPS (TTM)
-1.81
Profit Margin (>10% good)
-1.84%
Operating Margin (TTM) (higher better)
-0.89%
ROE (TTM) (>15% strong)
-9.34%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.99
Momentum
Bearish momentum
Value
0.2359
Previous
0.2420
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025